The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, the gravity of unmet medical needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Biosimilars in Pharmaceuticals: Recombinant antibodies for cytotoxic T-cells.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Recombinant antibodies for cytotoxic T-cells is a key innovation area in biosimilars
Cytotoxic T-cells, also called killer T-cells or cytotoxic T lymphocytes, are a type of white blood cell (WBC) or lymphocyte. Cytotoxic T-cells play an important role in the body’s immune defence by identifying and eliminating cancer cells, and other pathogens. Monoclonal antibodies, especially bi-specific monoclonal antibodies, target the T-cell Receptor (TCR) complex and activate these cells, directing them toward cancer and infected cells, killing them.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 290+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of recombinant antibodies for cytotoxic T-cells.
Key players in recombinant antibodies for cytotoxic T-cells – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to recombinant antibodies for cytotoxic T-cells
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Bristol-Myers Squibb||923||Unlock company profile|
|Cellectis||534||Unlock company profile|
|Memorial Sloan Kettering Cancer Center||520||Unlock company profile|
|Gilead Sciences||420||Unlock company profile|
|bluebird bio||407||Unlock company profile|
|Autolus||366||Unlock company profile|
|Amgen||331||Unlock company profile|
|City of Hope||320||Unlock company profile|
|Fred Hutchinson Cancer Research Center||297||Unlock company profile|
|Eureka Therapeutics||288||Unlock company profile|
|Miltenyi Biotec||227||Unlock company profile|
|CARsgen Therapeutics||198||Unlock company profile|
|Seattle Children's Hospital||188||Unlock company profile|
|Pfizer||175||Unlock company profile|
|Regeneron Pharmaceuticals||169||Unlock company profile|
|CRISPR Therapeutics||138||Unlock company profile|
|ImmunityBio||135||Unlock company profile|
|Nanjing Legend Biotech||131||Unlock company profile|
|BioNTech||127||Unlock company profile|
|TCR2 Therapeutics||123||Unlock company profile|
|United States Of America||117||Unlock company profile|
|Precision Biosciences||106||Unlock company profile|
|Biogen||106||Unlock company profile|
|C. H. Boehringer Sohn||104||Unlock company profile|
|Immatics||101||Unlock company profile|
|Alpine Immune Sciences||99||Unlock company profile|
|Aleta Biotherapeutics||99||Unlock company profile|
|Allogene Therapeutics||93||Unlock company profile|
|Innovative Cellular Therapeutics||92||Unlock company profile|
|Xencor||88||Unlock company profile|
|Massachusetts General Hospital||86||Unlock company profile|
|Inhibrx||86||Unlock company profile|
|F. Hoffmann-La Roche||85||Unlock company profile|
|PT Soho Global Health Tbk||81||Unlock company profile|
|Poseida Therapeutics||81||Unlock company profile|
|Precigen||79||Unlock company profile|
|Merck & Co||77||Unlock company profile|
|iCell Gene Therapeutics||68||Unlock company profile|
|Fate Therapeutics||65||Unlock company profile|
|Bellicum Pharmaceuticals||65||Unlock company profile|
|Sangamo Therapeutics||64||Unlock company profile|
|Novartis||62||Unlock company profile|
|GSK||62||Unlock company profile|
|EXUMA Biotech||57||Unlock company profile|
|TRON gGmbH||54||Unlock company profile|
|Editas Medicine||52||Unlock company profile|
|Genscript Biotech||51||Unlock company profile|
|AbbVie||50||Unlock company profile|
|Johnson & Johnson||49||Unlock company profile|
|CytoImmune Therapeutics||49||Unlock company profile|
Source: GlobalData Patent Analytics
Amgen, one of the leading players, has a large presence within the biologics market. Its Bispecific T-cell Engager (BiTE) technology is a cornerstone in the development of bi-specific antibodies. BiTE technology is designed to overcome cancer cells’ evasion of the immune system by engaging patients’ own T cells to directly target cancer cells. BiTE molecules comprise two flexibly-linked, single-chain antibodies, with one designed to bind specifically to a selected tumour-associated antigen and the other to bind to CD3 antigens found on T cells.
In terms of application diversity, Fate Therapeutics is the leading company, followed by Immatics and Biogen. By means of geographic reach, Boehringer holds the top position. Amgen and Pfizer are in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.